nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ABCB1—kidney cancer	0.299	1	CbGaD
Methylprednisolone—ABCB1—Temsirolimus—kidney cancer	0.0634	0.134	CbGbCtD
Methylprednisolone—CYP3A4—Everolimus—kidney cancer	0.0563	0.119	CbGbCtD
Methylprednisolone—CYP3A4—Temsirolimus—kidney cancer	0.038	0.0802	CbGbCtD
Methylprednisolone—ABCB1—Pazopanib—kidney cancer	0.0333	0.0703	CbGbCtD
Methylprednisolone—ABCB1—Dactinomycin—kidney cancer	0.0305	0.0643	CbGbCtD
Methylprednisolone—ABCB1—Gemcitabine—kidney cancer	0.0241	0.0509	CbGbCtD
Methylprednisolone—ABCB1—Erlotinib—kidney cancer	0.0238	0.0502	CbGbCtD
Methylprednisolone—ABCB1—Paclitaxel—kidney cancer	0.0218	0.046	CbGbCtD
Methylprednisolone—CYP3A4—Pazopanib—kidney cancer	0.02	0.0422	CbGbCtD
Methylprednisolone—ABCB1—Sorafenib—kidney cancer	0.0193	0.0408	CbGbCtD
Methylprednisolone—ABCB1—Vinblastine—kidney cancer	0.0191	0.0403	CbGbCtD
Methylprednisolone—ABCB1—Vincristine—kidney cancer	0.0188	0.0396	CbGbCtD
Methylprednisolone—ABCB1—Sunitinib—kidney cancer	0.0157	0.0331	CbGbCtD
Methylprednisolone—CYP3A4—Erlotinib—kidney cancer	0.0142	0.0301	CbGbCtD
Methylprednisolone—CYP3A4—Paclitaxel—kidney cancer	0.013	0.0275	CbGbCtD
Methylprednisolone—ABCB1—Doxorubicin—kidney cancer	0.0117	0.0248	CbGbCtD
Methylprednisolone—CYP3A4—Sorafenib—kidney cancer	0.0116	0.0245	CbGbCtD
Methylprednisolone—CYP3A4—Vinblastine—kidney cancer	0.0114	0.0241	CbGbCtD
Methylprednisolone—CYP3A4—Vincristine—kidney cancer	0.0112	0.0237	CbGbCtD
Methylprednisolone—CYP3A4—Sunitinib—kidney cancer	0.00939	0.0198	CbGbCtD
Methylprednisolone—CYP3A4—Doxorubicin—kidney cancer	0.00703	0.0148	CbGbCtD
Methylprednisolone—NR3C1—urine—kidney cancer	0.000772	0.239	CbGeAlD
Methylprednisolone—Hydrocortisone—ANXA1—kidney cancer	0.000599	0.255	CrCbGaD
Methylprednisolone—CYP3A4—urine—kidney cancer	0.000584	0.181	CbGeAlD
Methylprednisolone—Dexamethasone—ANXA1—kidney cancer	0.000446	0.19	CrCbGaD
Methylprednisolone—Triamcinolone—BCHE—kidney cancer	0.000273	0.116	CrCbGaD
Methylprednisolone—Clobetasol propionate—CYP1A1—kidney cancer	0.000256	0.109	CrCbGaD
Methylprednisolone—NR3C1—nephron tubule—kidney cancer	0.000208	0.0644	CbGeAlD
Methylprednisolone—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000191	0.0381	CbGpPWpGaD
Methylprednisolone—NR3C1—renal system—kidney cancer	0.000189	0.0585	CbGeAlD
Methylprednisolone—NR3C1—kidney—kidney cancer	0.000183	0.0566	CbGeAlD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—kidney cancer	0.000181	0.0361	CbGpPWpGaD
Methylprednisolone—NR3C1—cortex of kidney—kidney cancer	0.000178	0.0551	CbGeAlD
Methylprednisolone—NR3C1—gonad—kidney cancer	0.000169	0.0525	CbGeAlD
Methylprednisolone—NR3C1—cardiac atrium—kidney cancer	0.000169	0.0524	CbGeAlD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—HNF1A—kidney cancer	0.000162	0.0322	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—FOSL2—kidney cancer	0.000154	0.0307	CbGpPWpGaD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—EGR1—kidney cancer	0.000144	0.0286	CbGpPWpGaD
Methylprednisolone—CYP3A4—renal system—kidney cancer	0.000143	0.0443	CbGeAlD
Methylprednisolone—CYP3A4—kidney—kidney cancer	0.000138	0.0428	CbGeAlD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—TFE3—kidney cancer	0.000131	0.0261	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—CER1—kidney cancer	0.000126	0.0251	CbGpPWpGaD
Methylprednisolone—Triamcinolone—PTGS2—kidney cancer	0.000126	0.0535	CrCbGaD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.00012	0.024	CbGpPWpGaD
Methylprednisolone—Fatigue—Dactinomycin—kidney cancer	0.00012	0.000555	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Gemcitabine—kidney cancer	0.000118	0.000545	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Doxorubicin—kidney cancer	0.000117	0.000542	CcSEcCtD
Methylprednisolone—Infection—Gemcitabine—kidney cancer	0.000117	0.000542	CcSEcCtD
Methylprednisolone—Dizziness—Vinblastine—kidney cancer	0.000117	0.00054	CcSEcCtD
Methylprednisolone—Dizziness—Everolimus—kidney cancer	0.000117	0.000538	CcSEcCtD
Methylprednisolone—Abdominal pain—Sunitinib—kidney cancer	0.000116	0.000537	CcSEcCtD
Methylprednisolone—Diarrhoea—Erlotinib—kidney cancer	0.000116	0.000537	CcSEcCtD
Methylprednisolone—Hypotension—Vincristine—kidney cancer	0.000116	0.000537	CcSEcCtD
Methylprednisolone—Bradycardia—Capecitabine—kidney cancer	0.000116	0.000537	CcSEcCtD
Methylprednisolone—Nervous system disorder—Gemcitabine—kidney cancer	0.000116	0.000535	CcSEcCtD
Methylprednisolone—Feeling abnormal—Dactinomycin—kidney cancer	0.000115	0.00053	CcSEcCtD
Methylprednisolone—Haemoglobin—Capecitabine—kidney cancer	0.000115	0.00053	CcSEcCtD
Methylprednisolone—Skin disorder—Gemcitabine—kidney cancer	0.000115	0.00053	CcSEcCtD
Methylprednisolone—Rhinitis—Capecitabine—kidney cancer	0.000115	0.000529	CcSEcCtD
Methylprednisolone—Haemorrhage—Capecitabine—kidney cancer	0.000114	0.000527	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Gemcitabine—kidney cancer	0.000114	0.000527	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000114	0.000526	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000113	0.000524	CcSEcCtD
Methylprednisolone—Increased appetite—Doxorubicin—kidney cancer	0.000113	0.000523	CcSEcCtD
Methylprednisolone—Hypersensitivity—Sorafenib—kidney cancer	0.000113	0.00052	CcSEcCtD
Methylprednisolone—Insomnia—Vincristine—kidney cancer	0.000113	0.00052	CcSEcCtD
Methylprednisolone—Vomiting—Vinblastine—kidney cancer	0.000113	0.000519	CcSEcCtD
Methylprednisolone—Dizziness—Erlotinib—kidney cancer	0.000112	0.000519	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Paclitaxel—kidney cancer	0.000112	0.000519	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Capecitabine—kidney cancer	0.000112	0.000518	CcSEcCtD
Methylprednisolone—Vomiting—Everolimus—kidney cancer	0.000112	0.000517	CcSEcCtD
Methylprednisolone—Paraesthesia—Vincristine—kidney cancer	0.000112	0.000516	CcSEcCtD
Methylprednisolone—ABCB1—nephron tubule—kidney cancer	0.000111	0.0345	CbGeAlD
Methylprednisolone—Rash—Everolimus—kidney cancer	0.000111	0.000513	CcSEcCtD
Methylprednisolone—Dermatitis—Everolimus—kidney cancer	0.000111	0.000512	CcSEcCtD
Methylprednisolone—Headache—Vinblastine—kidney cancer	0.000111	0.000512	CcSEcCtD
Methylprednisolone—Angioedema—Paclitaxel—kidney cancer	0.000111	0.000511	CcSEcCtD
Methylprednisolone—Headache—Everolimus—kidney cancer	0.00011	0.00051	CcSEcCtD
Methylprednisolone—Hypotension—Gemcitabine—kidney cancer	0.00011	0.000509	CcSEcCtD
Methylprednisolone—Abdominal pain—Dactinomycin—kidney cancer	0.00011	0.000508	CcSEcCtD
Methylprednisolone—Visual impairment—Capecitabine—kidney cancer	0.00011	0.000508	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.00011	0.000508	CcSEcCtD
Methylprednisolone—Asthenia—Sorafenib—kidney cancer	0.00011	0.000507	CcSEcCtD
Methylprednisolone—Malaise—Paclitaxel—kidney cancer	0.000109	0.000504	CcSEcCtD
Methylprednisolone—Cardiac failure—Doxorubicin—kidney cancer	0.000109	0.000503	CcSEcCtD
Methylprednisolone—Vertigo—Paclitaxel—kidney cancer	0.000109	0.000502	CcSEcCtD
Methylprednisolone—Syncope—Paclitaxel—kidney cancer	0.000109	0.000502	CcSEcCtD
Methylprednisolone—Hypersensitivity—Sunitinib—kidney cancer	0.000108	0.000501	CcSEcCtD
Methylprednisolone—Pruritus—Sorafenib—kidney cancer	0.000108	0.0005	CcSEcCtD
Methylprednisolone—Vomiting—Erlotinib—kidney cancer	0.000108	0.000499	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000108	0.000497	CcSEcCtD
Methylprednisolone—Fatigue—Vincristine—kidney cancer	0.000107	0.000495	CcSEcCtD
Methylprednisolone—Rash—Erlotinib—kidney cancer	0.000107	0.000495	CcSEcCtD
Methylprednisolone—Dermatitis—Erlotinib—kidney cancer	0.000107	0.000494	CcSEcCtD
Methylprednisolone—Insomnia—Gemcitabine—kidney cancer	0.000107	0.000493	CcSEcCtD
Methylprednisolone—Eye disorder—Capecitabine—kidney cancer	0.000107	0.000493	CcSEcCtD
Methylprednisolone—Headache—Erlotinib—kidney cancer	0.000107	0.000492	CcSEcCtD
Methylprednisolone—Loss of consciousness—Paclitaxel—kidney cancer	0.000107	0.000492	CcSEcCtD
Methylprednisolone—Osteoarthritis—Doxorubicin—kidney cancer	0.000106	0.000491	CcSEcCtD
Methylprednisolone—Paraesthesia—Gemcitabine—kidney cancer	0.000106	0.00049	CcSEcCtD
Methylprednisolone—Cardiac disorder—Capecitabine—kidney cancer	0.000106	0.000489	CcSEcCtD
Methylprednisolone—Asthenia—Sunitinib—kidney cancer	0.000106	0.000487	CcSEcCtD
Methylprednisolone—Nausea—Vinblastine—kidney cancer	0.000105	0.000485	CcSEcCtD
Methylprednisolone—Convulsion—Paclitaxel—kidney cancer	0.000105	0.000485	CcSEcCtD
Methylprednisolone—Affect lability—Doxorubicin—kidney cancer	0.000105	0.000484	CcSEcCtD
Methylprednisolone—Nausea—Everolimus—kidney cancer	0.000105	0.000483	CcSEcCtD
Methylprednisolone—Diarrhoea—Sorafenib—kidney cancer	0.000105	0.000483	CcSEcCtD
Methylprednisolone—Hypertension—Paclitaxel—kidney cancer	0.000105	0.000483	CcSEcCtD
Methylprednisolone—Pruritus—Sunitinib—kidney cancer	0.000104	0.000481	CcSEcCtD
Methylprednisolone—Angiopathy—Capecitabine—kidney cancer	0.000104	0.000478	CcSEcCtD
Methylprednisolone—Immune system disorder—Capecitabine—kidney cancer	0.000103	0.000476	CcSEcCtD
Methylprednisolone—Myalgia—Paclitaxel—kidney cancer	0.000103	0.000476	CcSEcCtD
Methylprednisolone—Arthralgia—Paclitaxel—kidney cancer	0.000103	0.000476	CcSEcCtD
Methylprednisolone—Betamethasone—PTGS2—kidney cancer	0.000103	0.0438	CrCbGaD
Methylprednisolone—Mediastinal disorder—Capecitabine—kidney cancer	0.000103	0.000475	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—FOSL1—kidney cancer	0.000103	0.0205	CbGpPWpGaD
Methylprednisolone—Anxiety—Paclitaxel—kidney cancer	0.000103	0.000474	CcSEcCtD
Methylprednisolone—Hypersensitivity—Dactinomycin—kidney cancer	0.000103	0.000474	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000102	0.000473	CcSEcCtD
Methylprednisolone—Arrhythmia—Capecitabine—kidney cancer	0.000102	0.000471	CcSEcCtD
Methylprednisolone—Discomfort—Paclitaxel—kidney cancer	0.000102	0.00047	CcSEcCtD
Methylprednisolone—Fatigue—Gemcitabine—kidney cancer	0.000102	0.00047	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Vincristine—kidney cancer	0.000102	0.00047	CcSEcCtD
Methylprednisolone—Cardiac arrest—Doxorubicin—kidney cancer	0.000101	0.000467	CcSEcCtD
Methylprednisolone—Dizziness—Sorafenib—kidney cancer	0.000101	0.000467	CcSEcCtD
Methylprednisolone—ABCB1—renal system—kidney cancer	0.000101	0.0313	CbGeAlD
Methylprednisolone—Nausea—Erlotinib—kidney cancer	0.000101	0.000466	CcSEcCtD
Methylprednisolone—Mood swings—Doxorubicin—kidney cancer	0.000101	0.000465	CcSEcCtD
Methylprednisolone—Diarrhoea—Sunitinib—kidney cancer	0.000101	0.000465	CcSEcCtD
Methylprednisolone—Mental disorder—Capecitabine—kidney cancer	0.0001	0.000462	CcSEcCtD
Methylprednisolone—Asthenia—Dactinomycin—kidney cancer	0.0001	0.000461	CcSEcCtD
Methylprednisolone—Confusional state—Paclitaxel—kidney cancer	9.97e-05	0.00046	CcSEcCtD
Methylprednisolone—Erythema—Capecitabine—kidney cancer	9.95e-05	0.000459	CcSEcCtD
Methylprednisolone—Malnutrition—Capecitabine—kidney cancer	9.95e-05	0.000459	CcSEcCtD
Methylprednisolone—ABCB1—Allograft Rejection—HARS—kidney cancer	9.93e-05	0.0198	CbGpPWpGaD
Methylprednisolone—Anaphylactic shock—Paclitaxel—kidney cancer	9.89e-05	0.000456	CcSEcCtD
Methylprednisolone—Abdominal pain—Vincristine—kidney cancer	9.85e-05	0.000454	CcSEcCtD
Methylprednisolone—Infection—Paclitaxel—kidney cancer	9.83e-05	0.000453	CcSEcCtD
Methylprednisolone—ABCB1—kidney—kidney cancer	9.77e-05	0.0303	CbGeAlD
Methylprednisolone—Dizziness—Sunitinib—kidney cancer	9.74e-05	0.000449	CcSEcCtD
Methylprednisolone—Feeling abnormal—Gemcitabine—kidney cancer	9.74e-05	0.000449	CcSEcCtD
Methylprednisolone—Shock—Paclitaxel—kidney cancer	9.73e-05	0.000449	CcSEcCtD
Methylprednisolone—Vomiting—Sorafenib—kidney cancer	9.73e-05	0.000449	CcSEcCtD
Methylprednisolone—Prednisone—ABCB1—kidney cancer	9.7e-05	0.0412	CrCbGaD
Methylprednisolone—Nervous system disorder—Paclitaxel—kidney cancer	9.7e-05	0.000448	CcSEcCtD
Methylprednisolone—Tachycardia—Paclitaxel—kidney cancer	9.65e-05	0.000445	CcSEcCtD
Methylprednisolone—Rash—Sorafenib—kidney cancer	9.65e-05	0.000445	CcSEcCtD
Methylprednisolone—Dermatitis—Sorafenib—kidney cancer	9.64e-05	0.000445	CcSEcCtD
Methylprednisolone—Breast disorder—Doxorubicin—kidney cancer	9.62e-05	0.000444	CcSEcCtD
Methylprednisolone—Skin disorder—Paclitaxel—kidney cancer	9.61e-05	0.000443	CcSEcCtD
Methylprednisolone—Dexamethasone—CYP1A1—kidney cancer	9.59e-05	0.0408	CrCbGaD
Methylprednisolone—Headache—Sorafenib—kidney cancer	9.59e-05	0.000442	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Paclitaxel—kidney cancer	9.56e-05	0.000441	CcSEcCtD
Methylprednisolone—Diarrhoea—Dactinomycin—kidney cancer	9.54e-05	0.00044	CcSEcCtD
Methylprednisolone—ABCB1—cortex of kidney—kidney cancer	9.52e-05	0.0295	CbGeAlD
Methylprednisolone—Alanine aminotransferase increased—Doxorubicin—kidney cancer	9.39e-05	0.000433	CcSEcCtD
Methylprednisolone—Muscular weakness—Doxorubicin—kidney cancer	9.39e-05	0.000433	CcSEcCtD
Methylprednisolone—Vomiting—Sunitinib—kidney cancer	9.36e-05	0.000432	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—HNF1B—kidney cancer	9.3e-05	0.0185	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—BMP7—kidney cancer	9.3e-05	0.0185	CbGpPWpGaD
Methylprednisolone—Rash—Sunitinib—kidney cancer	9.28e-05	0.000428	CcSEcCtD
Methylprednisolone—Dermatitis—Sunitinib—kidney cancer	9.28e-05	0.000428	CcSEcCtD
Methylprednisolone—Abdominal distension—Doxorubicin—kidney cancer	9.26e-05	0.000427	CcSEcCtD
Methylprednisolone—Hypotension—Paclitaxel—kidney cancer	9.24e-05	0.000427	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Capecitabine—kidney cancer	9.23e-05	0.000426	CcSEcCtD
Methylprednisolone—Headache—Sunitinib—kidney cancer	9.22e-05	0.000426	CcSEcCtD
Methylprednisolone—Hypersensitivity—Vincristine—kidney cancer	9.18e-05	0.000423	CcSEcCtD
Methylprednisolone—Nausea—Sorafenib—kidney cancer	9.09e-05	0.000419	CcSEcCtD
Methylprednisolone—ABCB1—gonad—kidney cancer	9.06e-05	0.0281	CbGeAlD
Methylprednisolone—Pancreatitis—Doxorubicin—kidney cancer	9.02e-05	0.000416	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.01e-05	0.000416	CcSEcCtD
Methylprednisolone—Malaise—Capecitabine—kidney cancer	8.97e-05	0.000414	CcSEcCtD
Methylprednisolone—Insomnia—Paclitaxel—kidney cancer	8.95e-05	0.000413	CcSEcCtD
Methylprednisolone—Prednisolone—ABCB1—kidney cancer	8.94e-05	0.038	CrCbGaD
Methylprednisolone—Vertigo—Capecitabine—kidney cancer	8.94e-05	0.000412	CcSEcCtD
Methylprednisolone—Asthenia—Vincristine—kidney cancer	8.94e-05	0.000412	CcSEcCtD
Methylprednisolone—Syncope—Capecitabine—kidney cancer	8.92e-05	0.000412	CcSEcCtD
Methylprednisolone—Paraesthesia—Paclitaxel—kidney cancer	8.88e-05	0.00041	CcSEcCtD
Methylprednisolone—Vomiting—Dactinomycin—kidney cancer	8.86e-05	0.000409	CcSEcCtD
Methylprednisolone—Rash—Dactinomycin—kidney cancer	8.79e-05	0.000406	CcSEcCtD
Methylprednisolone—Betamethasone—ABCB1—kidney cancer	8.76e-05	0.0372	CrCbGaD
Methylprednisolone—Nausea—Sunitinib—kidney cancer	8.75e-05	0.000404	CcSEcCtD
Methylprednisolone—Loss of consciousness—Capecitabine—kidney cancer	8.74e-05	0.000403	CcSEcCtD
Methylprednisolone—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	8.72e-05	0.0174	CbGpPWpGaD
Methylprednisolone—Dyspepsia—Paclitaxel—kidney cancer	8.71e-05	0.000402	CcSEcCtD
Methylprednisolone—Hypertension—Capecitabine—kidney cancer	8.59e-05	0.000396	CcSEcCtD
Methylprednisolone—Fatigue—Paclitaxel—kidney cancer	8.53e-05	0.000394	CcSEcCtD
Methylprednisolone—Diarrhoea—Vincristine—kidney cancer	8.52e-05	0.000393	CcSEcCtD
Methylprednisolone—Asthenia—Gemcitabine—kidney cancer	8.48e-05	0.000391	CcSEcCtD
Methylprednisolone—Myalgia—Capecitabine—kidney cancer	8.47e-05	0.000391	CcSEcCtD
Methylprednisolone—Arthralgia—Capecitabine—kidney cancer	8.47e-05	0.000391	CcSEcCtD
Methylprednisolone—Anxiety—Capecitabine—kidney cancer	8.44e-05	0.000389	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	8.41e-05	0.000388	CcSEcCtD
Methylprednisolone—Weight increased—Doxorubicin—kidney cancer	8.37e-05	0.000386	CcSEcCtD
Methylprednisolone—Discomfort—Capecitabine—kidney cancer	8.37e-05	0.000386	CcSEcCtD
Methylprednisolone—Pruritus—Gemcitabine—kidney cancer	8.36e-05	0.000386	CcSEcCtD
Methylprednisolone—Nausea—Dactinomycin—kidney cancer	8.28e-05	0.000382	CcSEcCtD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—kidney cancer	8.27e-05	0.0165	CbGpPWpGaD
Methylprednisolone—Dizziness—Vincristine—kidney cancer	8.24e-05	0.00038	CcSEcCtD
Methylprednisolone—Infestation NOS—Doxorubicin—kidney cancer	8.2e-05	0.000379	CcSEcCtD
Methylprednisolone—Infestation—Doxorubicin—kidney cancer	8.2e-05	0.000379	CcSEcCtD
Methylprednisolone—Confusional state—Capecitabine—kidney cancer	8.19e-05	0.000378	CcSEcCtD
Methylprednisolone—Feeling abnormal—Paclitaxel—kidney cancer	8.15e-05	0.000376	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Paclitaxel—kidney cancer	8.09e-05	0.000373	CcSEcCtD
Methylprednisolone—Diarrhoea—Gemcitabine—kidney cancer	8.08e-05	0.000373	CcSEcCtD
Methylprednisolone—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	8.07e-05	0.0161	CbGpPWpGaD
Methylprednisolone—Infection—Capecitabine—kidney cancer	8.06e-05	0.000372	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Doxorubicin—kidney cancer	8.04e-05	0.000371	CcSEcCtD
Methylprednisolone—Shock—Capecitabine—kidney cancer	7.99e-05	0.000369	CcSEcCtD
Methylprednisolone—Nervous system disorder—Capecitabine—kidney cancer	7.96e-05	0.000367	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—JUND—kidney cancer	7.95e-05	0.0158	CbGpPWpGaD
Methylprednisolone—Tachycardia—Capecitabine—kidney cancer	7.92e-05	0.000366	CcSEcCtD
Methylprednisolone—Vomiting—Vincristine—kidney cancer	7.92e-05	0.000365	CcSEcCtD
Methylprednisolone—Skin disorder—Capecitabine—kidney cancer	7.88e-05	0.000364	CcSEcCtD
Methylprednisolone—Sweating—Doxorubicin—kidney cancer	7.87e-05	0.000363	CcSEcCtD
Methylprednisolone—Urticaria—Paclitaxel—kidney cancer	7.86e-05	0.000363	CcSEcCtD
Methylprednisolone—Rash—Vincristine—kidney cancer	7.85e-05	0.000362	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Capecitabine—kidney cancer	7.85e-05	0.000362	CcSEcCtD
Methylprednisolone—Dermatitis—Vincristine—kidney cancer	7.85e-05	0.000362	CcSEcCtD
Methylprednisolone—Abdominal pain—Paclitaxel—kidney cancer	7.82e-05	0.000361	CcSEcCtD
Methylprednisolone—Headache—Vincristine—kidney cancer	7.8e-05	0.00036	CcSEcCtD
Methylprednisolone—Hypotension—Capecitabine—kidney cancer	7.59e-05	0.00035	CcSEcCtD
Methylprednisolone—Vomiting—Gemcitabine—kidney cancer	7.51e-05	0.000347	CcSEcCtD
Methylprednisolone—Bradycardia—Doxorubicin—kidney cancer	7.5e-05	0.000346	CcSEcCtD
Methylprednisolone—Rash—Gemcitabine—kidney cancer	7.45e-05	0.000344	CcSEcCtD
Methylprednisolone—Dermatitis—Gemcitabine—kidney cancer	7.44e-05	0.000343	CcSEcCtD
Methylprednisolone—Haemoglobin—Doxorubicin—kidney cancer	7.4e-05	0.000342	CcSEcCtD
Methylprednisolone—Headache—Gemcitabine—kidney cancer	7.4e-05	0.000342	CcSEcCtD
Methylprednisolone—Nausea—Vincristine—kidney cancer	7.4e-05	0.000341	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.4e-05	0.000341	CcSEcCtD
Methylprednisolone—Rhinitis—Doxorubicin—kidney cancer	7.38e-05	0.000341	CcSEcCtD
Methylprednisolone—Haemorrhage—Doxorubicin—kidney cancer	7.37e-05	0.00034	CcSEcCtD
Methylprednisolone—Insomnia—Capecitabine—kidney cancer	7.34e-05	0.000339	CcSEcCtD
Methylprednisolone—Paraesthesia—Capecitabine—kidney cancer	7.29e-05	0.000336	CcSEcCtD
Methylprednisolone—Hypersensitivity—Paclitaxel—kidney cancer	7.29e-05	0.000336	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Doxorubicin—kidney cancer	7.24e-05	0.000334	CcSEcCtD
Methylprednisolone—Dyspepsia—Capecitabine—kidney cancer	7.15e-05	0.00033	CcSEcCtD
Methylprednisolone—Visual impairment—Doxorubicin—kidney cancer	7.1e-05	0.000328	CcSEcCtD
Methylprednisolone—Asthenia—Paclitaxel—kidney cancer	7.1e-05	0.000327	CcSEcCtD
Methylprednisolone—Nausea—Gemcitabine—kidney cancer	7.02e-05	0.000324	CcSEcCtD
Methylprednisolone—Fatigue—Capecitabine—kidney cancer	7e-05	0.000323	CcSEcCtD
Methylprednisolone—Pruritus—Paclitaxel—kidney cancer	7e-05	0.000323	CcSEcCtD
Methylprednisolone—Eye disorder—Doxorubicin—kidney cancer	6.88e-05	0.000318	CcSEcCtD
Methylprednisolone—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	6.85e-05	0.0136	CbGpPWpGaD
Methylprednisolone—Hydrocortisone—ABCB1—kidney cancer	6.84e-05	0.0291	CrCbGaD
Methylprednisolone—Cardiac disorder—Doxorubicin—kidney cancer	6.84e-05	0.000315	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—EPAS1—kidney cancer	6.8e-05	0.0135	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—HNF1A—kidney cancer	6.8e-05	0.0135	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Paclitaxel—kidney cancer	6.77e-05	0.000312	CcSEcCtD
Methylprednisolone—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	6.76e-05	0.0135	CbGpPWpGaD
Methylprednisolone—Feeling abnormal—Capecitabine—kidney cancer	6.69e-05	0.000309	CcSEcCtD
Methylprednisolone—Angiopathy—Doxorubicin—kidney cancer	6.68e-05	0.000308	CcSEcCtD
Methylprednisolone—Immune system disorder—Doxorubicin—kidney cancer	6.65e-05	0.000307	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Capecitabine—kidney cancer	6.64e-05	0.000306	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Doxorubicin—kidney cancer	6.64e-05	0.000306	CcSEcCtD
Methylprednisolone—Arrhythmia—Doxorubicin—kidney cancer	6.58e-05	0.000304	CcSEcCtD
Methylprednisolone—Dizziness—Paclitaxel—kidney cancer	6.54e-05	0.000302	CcSEcCtD
Methylprednisolone—Mental disorder—Doxorubicin—kidney cancer	6.45e-05	0.000298	CcSEcCtD
Methylprednisolone—Urticaria—Capecitabine—kidney cancer	6.45e-05	0.000298	CcSEcCtD
Methylprednisolone—Abdominal pain—Capecitabine—kidney cancer	6.42e-05	0.000296	CcSEcCtD
Methylprednisolone—Malnutrition—Doxorubicin—kidney cancer	6.41e-05	0.000296	CcSEcCtD
Methylprednisolone—Erythema—Doxorubicin—kidney cancer	6.41e-05	0.000296	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—EGR1—kidney cancer	6.32e-05	0.0126	CbGpPWpGaD
Methylprednisolone—Vomiting—Paclitaxel—kidney cancer	6.29e-05	0.00029	CcSEcCtD
Methylprednisolone—Rash—Paclitaxel—kidney cancer	6.24e-05	0.000288	CcSEcCtD
Methylprednisolone—Dermatitis—Paclitaxel—kidney cancer	6.23e-05	0.000288	CcSEcCtD
Methylprednisolone—Headache—Paclitaxel—kidney cancer	6.2e-05	0.000286	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—PGK1—kidney cancer	6.02e-05	0.012	CbGpPWpGaD
Methylprednisolone—Dexamethasone—PTGS2—kidney cancer	5.99e-05	0.0255	CrCbGaD
Methylprednisolone—Hypersensitivity—Capecitabine—kidney cancer	5.98e-05	0.000276	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Doxorubicin—kidney cancer	5.95e-05	0.000274	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IL13—kidney cancer	5.88e-05	0.0117	CbGpPWpGaD
Methylprednisolone—Nausea—Paclitaxel—kidney cancer	5.88e-05	0.000271	CcSEcCtD
Methylprednisolone—Asthenia—Capecitabine—kidney cancer	5.82e-05	0.000269	CcSEcCtD
Methylprednisolone—Malaise—Doxorubicin—kidney cancer	5.78e-05	0.000267	CcSEcCtD
Methylprednisolone—Vertigo—Doxorubicin—kidney cancer	5.76e-05	0.000266	CcSEcCtD
Methylprednisolone—Syncope—Doxorubicin—kidney cancer	5.75e-05	0.000265	CcSEcCtD
Methylprednisolone—Pruritus—Capecitabine—kidney cancer	5.74e-05	0.000265	CcSEcCtD
Methylprednisolone—ABCB1—Allograft Rejection—LRRK2—kidney cancer	5.7e-05	0.0114	CbGpPWpGaD
Methylprednisolone—Loss of consciousness—Doxorubicin—kidney cancer	5.64e-05	0.00026	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	5.6e-05	0.0112	CbGpPWpGaD
Methylprednisolone—Convulsion—Doxorubicin—kidney cancer	5.56e-05	0.000256	CcSEcCtD
Methylprednisolone—Diarrhoea—Capecitabine—kidney cancer	5.55e-05	0.000256	CcSEcCtD
Methylprednisolone—Hypertension—Doxorubicin—kidney cancer	5.54e-05	0.000255	CcSEcCtD
Methylprednisolone—Myalgia—Doxorubicin—kidney cancer	5.46e-05	0.000252	CcSEcCtD
Methylprednisolone—Arthralgia—Doxorubicin—kidney cancer	5.46e-05	0.000252	CcSEcCtD
Methylprednisolone—Anxiety—Doxorubicin—kidney cancer	5.44e-05	0.000251	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.42e-05	0.00025	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—JUNB—kidney cancer	5.41e-05	0.0108	CbGpPWpGaD
Methylprednisolone—Discomfort—Doxorubicin—kidney cancer	5.39e-05	0.000249	CcSEcCtD
Methylprednisolone—Dizziness—Capecitabine—kidney cancer	5.37e-05	0.000248	CcSEcCtD
Methylprednisolone—Confusional state—Doxorubicin—kidney cancer	5.28e-05	0.000243	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Doxorubicin—kidney cancer	5.23e-05	0.000241	CcSEcCtD
Methylprednisolone—Infection—Doxorubicin—kidney cancer	5.2e-05	0.00024	CcSEcCtD
Methylprednisolone—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	5.16e-05	0.0103	CbGpPWpGaD
Methylprednisolone—Vomiting—Capecitabine—kidney cancer	5.16e-05	0.000238	CcSEcCtD
Methylprednisolone—Shock—Doxorubicin—kidney cancer	5.15e-05	0.000238	CcSEcCtD
Methylprednisolone—Nervous system disorder—Doxorubicin—kidney cancer	5.13e-05	0.000237	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—CA9—kidney cancer	5.12e-05	0.0102	CbGpPWpGaD
Methylprednisolone—Rash—Capecitabine—kidney cancer	5.12e-05	0.000236	CcSEcCtD
Methylprednisolone—Dermatitis—Capecitabine—kidney cancer	5.11e-05	0.000236	CcSEcCtD
Methylprednisolone—Tachycardia—Doxorubicin—kidney cancer	5.11e-05	0.000236	CcSEcCtD
Methylprednisolone—Dexamethasone—ABCB1—kidney cancer	5.1e-05	0.0217	CrCbGaD
Methylprednisolone—Headache—Capecitabine—kidney cancer	5.09e-05	0.000235	CcSEcCtD
Methylprednisolone—Skin disorder—Doxorubicin—kidney cancer	5.08e-05	0.000235	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Doxorubicin—kidney cancer	5.06e-05	0.000233	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—EGR1—kidney cancer	5.06e-05	0.0101	CbGpPWpGaD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—kidney cancer	4.98e-05	0.00992	CbGpPWpGaD
Methylprednisolone—Hypotension—Doxorubicin—kidney cancer	4.89e-05	0.000226	CcSEcCtD
Methylprednisolone—Nausea—Capecitabine—kidney cancer	4.82e-05	0.000222	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.77e-05	0.00022	CcSEcCtD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK1—kidney cancer	4.74e-05	0.00944	CbGpPWpGaD
Methylprednisolone—Insomnia—Doxorubicin—kidney cancer	4.73e-05	0.000218	CcSEcCtD
Methylprednisolone—Paraesthesia—Doxorubicin—kidney cancer	4.7e-05	0.000217	CcSEcCtD
Methylprednisolone—Dyspepsia—Doxorubicin—kidney cancer	4.61e-05	0.000213	CcSEcCtD
Methylprednisolone—Fatigue—Doxorubicin—kidney cancer	4.51e-05	0.000208	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—EGR1—kidney cancer	4.46e-05	0.00888	CbGpPWpGaD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	4.42e-05	0.0088	CbGpPWpGaD
Methylprednisolone—Feeling abnormal—Doxorubicin—kidney cancer	4.31e-05	0.000199	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Doxorubicin—kidney cancer	4.28e-05	0.000197	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—HIF1A—kidney cancer	4.27e-05	0.0085	CbGpPWpGaD
Methylprednisolone—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	4.27e-05	0.0085	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HSPD1—kidney cancer	4.19e-05	0.00834	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—kidney cancer	4.17e-05	0.0083	CbGpPWpGaD
Methylprednisolone—Urticaria—Doxorubicin—kidney cancer	4.16e-05	0.000192	CcSEcCtD
Methylprednisolone—Abdominal pain—Doxorubicin—kidney cancer	4.14e-05	0.000191	CcSEcCtD
Methylprednisolone—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	4.1e-05	0.00816	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—kidney cancer	3.92e-05	0.0078	CbGpPWpGaD
Methylprednisolone—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	3.88e-05	0.00773	CbGpPWpGaD
Methylprednisolone—Hypersensitivity—Doxorubicin—kidney cancer	3.86e-05	0.000178	CcSEcCtD
Methylprednisolone—Asthenia—Doxorubicin—kidney cancer	3.75e-05	0.000173	CcSEcCtD
Methylprednisolone—CYP3A4—Irinotecan Pathway—APC—kidney cancer	3.72e-05	0.00741	CbGpPWpGaD
Methylprednisolone—Pruritus—Doxorubicin—kidney cancer	3.7e-05	0.000171	CcSEcCtD
Methylprednisolone—Diarrhoea—Doxorubicin—kidney cancer	3.58e-05	0.000165	CcSEcCtD
Methylprednisolone—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	3.57e-05	0.00711	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—HIF1A—kidney cancer	3.52e-05	0.00701	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—IL13—kidney cancer	3.51e-05	0.007	CbGpPWpGaD
Methylprednisolone—Dizziness—Doxorubicin—kidney cancer	3.46e-05	0.00016	CcSEcCtD
Methylprednisolone—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	3.43e-05	0.00684	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	3.39e-05	0.00674	CbGpPWpGaD
Methylprednisolone—Vomiting—Doxorubicin—kidney cancer	3.33e-05	0.000154	CcSEcCtD
Methylprednisolone—Rash—Doxorubicin—kidney cancer	3.3e-05	0.000152	CcSEcCtD
Methylprednisolone—Dermatitis—Doxorubicin—kidney cancer	3.3e-05	0.000152	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—ACY1—kidney cancer	3.28e-05	0.00654	CbGpPWpGaD
Methylprednisolone—Headache—Doxorubicin—kidney cancer	3.28e-05	0.000151	CcSEcCtD
Methylprednisolone—ABCB1—Allograft Rejection—IL13—kidney cancer	3.25e-05	0.00648	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—APC—kidney cancer	3.17e-05	0.00632	CbGpPWpGaD
Methylprednisolone—Nausea—Doxorubicin—kidney cancer	3.11e-05	0.000143	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	3.07e-05	0.00611	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—EGR1—kidney cancer	2.66e-05	0.00531	CbGpPWpGaD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	2.66e-05	0.0053	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—JUN—kidney cancer	2.65e-05	0.00528	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—POMC—kidney cancer	2.6e-05	0.00518	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	2.54e-05	0.00505	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDKN2A—kidney cancer	2.52e-05	0.00501	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDKN1B—kidney cancer	2.23e-05	0.00444	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	2.22e-05	0.00441	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—IL2—kidney cancer	2.18e-05	0.00435	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—HARS—kidney cancer	2.18e-05	0.00435	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—CTNNB1—kidney cancer	2.16e-05	0.00429	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—HIF1A—kidney cancer	2.14e-05	0.00427	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—RELA—kidney cancer	2.13e-05	0.00425	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CCND1—kidney cancer	2.13e-05	0.00424	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—JUN—kidney cancer	2.12e-05	0.00423	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CTNNB1—kidney cancer	2.11e-05	0.0042	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—PTEN—kidney cancer	2.05e-05	0.00409	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	1.98e-05	0.00395	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IL2—kidney cancer	1.92e-05	0.00383	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	1.91e-05	0.00381	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	1.91e-05	0.00381	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—kidney cancer	1.89e-05	0.00376	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—JUN—kidney cancer	1.87e-05	0.00373	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	1.86e-05	0.00371	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—EIF5B—kidney cancer	1.85e-05	0.00369	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—kidney cancer	1.85e-05	0.00369	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	1.83e-05	0.00365	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	1.81e-05	0.00361	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	1.8e-05	0.00358	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	1.78e-05	0.00354	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYC—kidney cancer	1.71e-05	0.0034	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	1.59e-05	0.00317	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	1.58e-05	0.00314	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—kidney cancer	1.55e-05	0.00308	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—kidney cancer	1.52e-05	0.00302	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	1.48e-05	0.00295	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—MAPK1—kidney cancer	1.47e-05	0.00293	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	1.46e-05	0.00291	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	1.45e-05	0.00289	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TP53—kidney cancer	1.4e-05	0.00279	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	1.3e-05	0.00259	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	1.3e-05	0.00259	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—CTNNB1—kidney cancer	1.28e-05	0.00256	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—kidney cancer	1.23e-05	0.00246	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	1.22e-05	0.00243	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	1.22e-05	0.00242	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—JUNB—kidney cancer	1.2e-05	0.0024	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.2e-05	0.00239	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	1.19e-05	0.00238	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—EEF2—kidney cancer	1.19e-05	0.00238	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—TET2—kidney cancer	1.15e-05	0.00228	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—JUN—kidney cancer	1.12e-05	0.00223	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	1.11e-05	0.00221	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.1e-05	0.0022	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	1.07e-05	0.00213	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL2—kidney cancer	1.06e-05	0.00212	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	1.06e-05	0.00211	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.06e-05	0.00211	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—TCEB2—kidney cancer	1.05e-05	0.00209	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—TCEB1—kidney cancer	1.05e-05	0.00209	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	1.04e-05	0.00208	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	1.02e-05	0.00204	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	1.02e-05	0.00204	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	1.02e-05	0.00204	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—PTGS1—kidney cancer	9.9e-06	0.00197	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—CDKN2B—kidney cancer	9.79e-06	0.00195	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—VEGFA—kidney cancer	9.76e-06	0.00195	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ACY1—kidney cancer	9.11e-06	0.00182	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—VEGFA—kidney cancer	9.04e-06	0.0018	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.96e-06	0.00178	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—RPL14—kidney cancer	8.51e-06	0.0017	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PDHB—kidney cancer	7.75e-06	0.00154	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	7.46e-06	0.00149	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTP1—kidney cancer	7.32e-06	0.00146	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CCBL1—kidney cancer	7.28e-06	0.00145	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	7.22e-06	0.00144	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—HSPB1—kidney cancer	6.94e-06	0.00138	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—EIF4EBP1—kidney cancer	6.94e-06	0.00138	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTM1—kidney cancer	6.73e-06	0.00134	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	6.64e-06	0.00132	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PSMD7—kidney cancer	6.45e-06	0.00129	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	6.38e-06	0.00127	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PPAT—kidney cancer	6.31e-06	0.00126	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GLIPR1—kidney cancer	6.31e-06	0.00126	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	6.29e-06	0.00125	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—FH—kidney cancer	5.87e-06	0.00117	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—APRT—kidney cancer	5.87e-06	0.00117	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	5.85e-06	0.00117	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—JUNB—kidney cancer	5.79e-06	0.00115	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	5.79e-06	0.00115	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	5.66e-06	0.00113	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ACY1—kidney cancer	5.61e-06	0.00112	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GPC3—kidney cancer	5.52e-06	0.0011	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	5.39e-06	0.00107	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CA2—kidney cancer	5.37e-06	0.00107	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	5.36e-06	0.00107	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ALAD—kidney cancer	5.23e-06	0.00104	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	5.2e-06	0.00104	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	5.12e-06	0.00102	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ST3GAL2—kidney cancer	5.11e-06	0.00102	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	5.11e-06	0.00102	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	5.07e-06	0.00101	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ALDH1A1—kidney cancer	4.99e-06	0.000994	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	4.94e-06	0.000984	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PGK1—kidney cancer	4.79e-06	0.000953	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC5A3—kidney cancer	4.79e-06	0.000953	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PDHB—kidney cancer	4.77e-06	0.000951	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—POMC—kidney cancer	4.76e-06	0.000948	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—CDKN2B—kidney cancer	4.72e-06	0.000939	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—LDHB—kidney cancer	4.69e-06	0.000935	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CCBL1—kidney cancer	4.49e-06	0.000894	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	4.46e-06	0.000889	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.22e-06	0.000841	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.1e-06	0.000818	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CA9—kidney cancer	4.07e-06	0.000811	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	4.02e-06	0.0008	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PPAT—kidney cancer	3.89e-06	0.000775	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.89e-06	0.000775	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MYC—kidney cancer	3.8e-06	0.000756	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	3.79e-06	0.000756	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—APRT—kidney cancer	3.62e-06	0.000721	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—FH—kidney cancer	3.62e-06	0.000721	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.48e-06	0.000694	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CRABP1—kidney cancer	3.46e-06	0.000689	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GPC3—kidney cancer	3.4e-06	0.000678	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.37e-06	0.000672	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CA2—kidney cancer	3.31e-06	0.000659	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ALAD—kidney cancer	3.22e-06	0.000642	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ITPR2—kidney cancer	3.22e-06	0.000641	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.15e-06	0.000627	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.08e-06	0.000613	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PGK1—kidney cancer	2.95e-06	0.000587	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.95e-06	0.000587	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTT1—kidney cancer	2.93e-06	0.000584	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ACHE—kidney cancer	2.93e-06	0.000584	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—LDHB—kidney cancer	2.89e-06	0.000576	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SCARB1—kidney cancer	2.78e-06	0.000553	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS1—kidney cancer	2.75e-06	0.000548	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PSMD7—kidney cancer	2.7e-06	0.000537	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—BCHE—kidney cancer	2.56e-06	0.000509	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC5A5—kidney cancer	2.52e-06	0.000503	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CA9—kidney cancer	2.51e-06	0.000499	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC2A1—kidney cancer	2.44e-06	0.000486	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.32e-06	0.000463	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CRABP1—kidney cancer	2.13e-06	0.000425	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTP1—kidney cancer	2.03e-06	0.000405	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ITPR2—kidney cancer	1.98e-06	0.000395	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MAPK3—kidney cancer	1.88e-06	0.000374	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTM1—kidney cancer	1.87e-06	0.000372	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MYC—kidney cancer	1.83e-06	0.000364	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ACHE—kidney cancer	1.81e-06	0.00036	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTT1—kidney cancer	1.81e-06	0.00036	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP1A1—kidney cancer	1.77e-06	0.000353	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SCARB1—kidney cancer	1.71e-06	0.000341	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS1—kidney cancer	1.69e-06	0.000337	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PSMD7—kidney cancer	1.66e-06	0.000331	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—BCHE—kidney cancer	1.57e-06	0.000314	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.55e-06	0.00031	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.5e-06	0.000299	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—POMC—kidney cancer	1.32e-06	0.000263	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTP1—kidney cancer	1.25e-06	0.00025	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ABCB1—kidney cancer	1.19e-06	0.000236	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTM1—kidney cancer	1.15e-06	0.000229	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.09e-06	0.000217	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS2—kidney cancer	1.05e-06	0.00021	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTEN—kidney cancer	9.19e-07	0.000183	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—POMC—kidney cancer	8.14e-07	0.000162	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS2—kidney cancer	6.49e-07	0.000129	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CA—kidney cancer	6.48e-07	0.000129	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTEN—kidney cancer	5.66e-07	0.000113	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.99e-07	7.95e-05	CbGpPWpGaD
